Browsing by Author "Biliaminu Sikiru A"

Now showing 1 - 1 of 1
  • Item
    Atherogenic and Cardiovascular Risks of Women on Combined Oral Contraceptives: A Comparative Study
    (Wolters-Kluwer (MedKnow)., 2021-12) Jimoh Olanrewaju Saheed; Abdul Ishaq Funsho; Balogun Olayinka R; Biliaminu Sikiru A; Adeniran AS; Jimoh-Abdulghaffaar Hidaayah Oluwamayowa; Adesina Kikelomo T; Ahmed Abdullahi; Oladosu Wahab Olatunbosun
    Although combined oral contraceptive (COC) is commonly used in sub‑Saharan Africa, data on its cardiovascular disease risk remains scanty. The study aimed to determine serial serum lipid profiles and cardiovascular disease risks among COC‑users. Methods: This is a prospective, comparative multicentered study conducted at four health facilities in Nigeria. Participants were new users of contraceptives; 120 each of women initiating COCs (group I) and those initiating other forms of nonhormonal contraceptives (group II) were recruited and monitored over a 6‑month period. Serial lipid profile, blood pressure, and atherogenic risk for cardiovascular diseases were measured at recruitment (start) and scheduled follow‑up clinic visits at 3 months and 6 months for all participants. Statistical analysis was performed with SPSS (version 21.0) and P value < 0.05 was considered significant. Results: In all, 225 participants (111 COC‑users, 114 nonCOC‑users) that completed the study were aged 18 to 49 years. There was a statistically significant increase in the diastolic blood pressure (P = 0.001), Low Density Lipoprotein‑ Cholesterol (P = 0.038) and higher atherogenic risk (P = 0.001) among COC‑users compared to nonCOC‑users. The serial total serum cholesterol, triglyceride, High Density Lipoprotein, systolic blood pressure, and body mass index were higher among COC‑users but were not statistically significant compared to nonCOC‑users. Conclusion: Alterations in lipid profile and increased short‑term atherogenic risk for cardiovascular disease were reported among the COC‑users in this study. Serial lipid profile and atherogenic risk assessment for cardiovascular diseases are recommended for monitoring of COC‑users.